Indian made vaccine for meningitis has saved 250 million lives in Africa by the efforts of World Health Organization (WHO) and PATH, an NGO. MenAfriVac has been produced by the Serum Institute of India to reduce the transmission of meningococcal bacteria and create a drastic drop in illness and death rates from meningitis. This conjugate vaccine was administered to those in the age group of 1 to 29 in 25 sub-Saharan African countries. This joint campaign has been a boon in the most affected place that is “the meningitis belt”. The whole cost of project in the market was a major low cost affair. Also, there was a great reduction in the meningitis cases thus can lower the significant funds in countries needed for public health problems. The Meningitis Vaccine Project team expects to receive a regulatory approval for vaccines for infants by the 2013. The research has also shown the safe use of MenAfriVac’s in infants. The vaccine development phases have been supported by various organizations such as United States Agency for International Development which gave significant funding to improve the meningitis epidemics in sub- Saharan Africa and the regulatory procedures for approval. This further, confirms the manufacturer for the vaccine to be the Serum Institute of India by the United States Food and Drug Administration’s (FDA) Centre for Biologics uation and Research

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related Research